PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9610742-1	1998	Aminobisphosphonates inhibit bone resorption but have been shown to elicit acute-phase-like elevations in interleukin-6 (IL-6) in bone in vitro.	aminobisphosphonates	0-20	interleukin 6	Rattus norvegicus	106-119
11313389-1	2001	Human gammadelta T cells respond to nonpeptide Ags such as pyrophosphomonoesters and alkylamines in a gammadelta TCR-dependent manner in the absence of other APCS: Recently, aminobisphosphonates such as pamidronate have also been shown to activate human gammadelta T cells.	aminobisphosphonates	174-194	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	113-116
10928970-0	2000	Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.	aminobisphosphonates	60-80	interleukin 1 complex	Mus musculus	15-28
10887096-4	2000	The proliferative response of gamma delta T cells to aminobisphosphonates was IL-2 dependent, whereas activation of gamma delta T cells (up-regulation of CD25 and CD69) occurred in the absence of exogenous cytokines.	aminobisphosphonates	53-73	interleukin 2	Homo sapiens	78-82
9831909-2	1998	Aminobisphosphonates (aminoBPs), potent inhibitors of bone resorption, have been reported to induce inflammatory reactions such as fever and an increase in acute phase proteins in human patients, and to induce the histamine-forming enzyme, histidine decarboxylase, in mice.	aminobisphosphonates	0-20	histidine decarboxylase	Homo sapiens	240-263
9610742-1	1998	Aminobisphosphonates inhibit bone resorption but have been shown to elicit acute-phase-like elevations in interleukin-6 (IL-6) in bone in vitro.	aminobisphosphonates	0-20	interleukin 6	Rattus norvegicus	121-125
30671590-8	2019	The clinical management of PDB has also evolved considerably, with the development of potent aminobisphosphonates such as zoledronic acid which, given as a single intravenous infusion, now allows a long-term disease remission in the majority of patients.	aminobisphosphonates	93-113	PDB1	Homo sapiens	27-30
9351880-20	1997	The cellular mechanism of the interaction among aminobisphosphonates, IL-6, and TNF alpha requires further investigations.	aminobisphosphonates	48-68	tumor necrosis factor	Homo sapiens	80-89
34952469-2	2022	These cells are activated by BTN3A1, which is expressed by pathogen-derived phosphoantigens (pAgs) or host-derived pAgs that accumulate in transformed cells or in cells exposed to aminobisphosphonates.	aminobisphosphonates	180-200	butyrophilin subfamily 3 member A1	Homo sapiens	29-35
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	sclerostin	Homo sapiens	54-58
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	parathyroid hormone	Homo sapiens	60-63
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	fibroblast growth factor 2	Homo sapiens	65-69
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	farnesyl diphosphate synthase	Homo sapiens	71-75
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	geranylgeranyl diphosphate synthase 1	Homo sapiens	77-82
31437227-5	2019	The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates.	aminobisphosphonates	141-161	LDL receptor related protein 5	Homo sapiens	88-92
8481841-11	1993	As granulocyte and granulocyte-macrophage colony-stimulating factors and interleukin-3 induce HDC in hematopoietic organs, and histamine has a hematopoietic activity, the HDC induction by aminobisphosphonates may be relevant to the proliferation of progenitor cells of macrophages, granulocytes, and osteoclasts.	aminobisphosphonates	188-208	histidine decarboxylase	Mus musculus	171-174
27103608-0	2017	Phytotoxicity of aminobisphosphonates targeting both delta1 -pyrroline-5-carboxylate reductase and glutamine synthetase.	aminobisphosphonates	17-37	glutamate-ammonia ligase	Homo sapiens	99-119
29163482-4	2017	Aminobisphosphonates (n-BPs), which inhibit farnesyl pyrophosphate synthase, a downstream enzyme of the mevalonate pathway, cause accumulation of upstream PAgs and therefore promote gammadelta T cell activation.	aminobisphosphonates	0-20	farnesyl diphosphate synthetase	Mus musculus	44-75
29989308-0	2018	Thermodynamics of the Interactions of Aminobisphosphonates and Their Calcium Complexes with Bovine Serum Albumin.	aminobisphosphonates	38-58	albumin	Homo sapiens	99-112
27103608-2	2017	Some aminobisphosphonates inhibit the activity of both glutamine synthetase and delta1 -pyrroline-5-carboxylate (P5C) reductase in vitro, but the relevance of the latter in vivo has yet to be proven.	aminobisphosphonates	5-25	glutamate-ammonia ligase	Homo sapiens	55-75
27103608-2	2017	Some aminobisphosphonates inhibit the activity of both glutamine synthetase and delta1 -pyrroline-5-carboxylate (P5C) reductase in vitro, but the relevance of the latter in vivo has yet to be proven.	aminobisphosphonates	5-25	pyrroline-5-carboxylate reductase 1	Homo sapiens	113-116
25796193-2	2015	As cancer patients are frequently treated with aminobisphosphonates (NBP), it is relevant to determine possible effects of NBP on CD1d-restricted glycolipid Ag-presentation to iNKT cells.	aminobisphosphonates	47-67	CD1d molecule	Homo sapiens	130-134
27681434-5	2016	The ability of SPARC to induce EMT depended on the localization and suppressive function of myeloid cells, and inhibition of the suppressive function MDSCs by administration of aminobisphosphonates could revert EMT, rendering SPARC-overexpressing tumor cells sensitive to Doxil.	aminobisphosphonates	177-197	secreted protein acidic and cysteine rich	Homo sapiens	226-231
22013129-2	2011	Aminobisphosphonates and alkylamines indirectly stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5"-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.	aminobisphosphonates	0-20	farnesyl diphosphate synthase	Homo sapiens	93-122
25796193-0	2015	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.	aminobisphosphonates	0-20	CD1d molecule	Homo sapiens	84-88
24311107-2	2014	Previous studies have shown that some polymorphisms of the gene encoding farnesyl diphosphate synthase (FDPS), the main target of aminobisphosphonates, modulate the response to these drugs.	aminobisphosphonates	130-150	farnesyl diphosphate synthase	Homo sapiens	73-102
24311107-2	2014	Previous studies have shown that some polymorphisms of the gene encoding farnesyl diphosphate synthase (FDPS), the main target of aminobisphosphonates, modulate the response to these drugs.	aminobisphosphonates	130-150	farnesyl diphosphate synthase	Homo sapiens	104-108
24311107-12	2014	In conclusion, these results suggest that polymorphisms of the FDPS gene may influence the bone response to various drugs targeting the mevalonate pathway, including not only aminobisphosphonates but also statins.	aminobisphosphonates	175-195	farnesyl diphosphate synthase	Homo sapiens	63-67
24162786-7	2014	Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing rituximab-induced antibody-dependent cell-mediated cytotoxicity.	aminobisphosphonates	0-20	killer cell lectin like receptor K1	Homo sapiens	189-194
24434328-3	2013	Aminobisphosphonates increase the endogenous pool of IPP in cells by blocking the enzyme farnesyl pyrophosphate synthase (FPPS) of the mevalonate pathway.	aminobisphosphonates	0-20	farnesyl diphosphate synthase	Homo sapiens	89-120
24434328-3	2013	Aminobisphosphonates increase the endogenous pool of IPP in cells by blocking the enzyme farnesyl pyrophosphate synthase (FPPS) of the mevalonate pathway.	aminobisphosphonates	0-20	farnesyl diphosphate synthase	Homo sapiens	122-126
23928436-4	2013	The authors reviewed pertinent literature related to basic bone histology, the pharmacokinetics of the aminobisphosphonates (nBP), diagnostic criteria for osteopenia/osteoporosis, and clinical applications of the antiresorptive agents.	aminobisphosphonates	103-123	NUBP iron-sulfur cluster assembly factor 1, cytosolic	Homo sapiens	125-128
21151198-1	2012	Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates.	aminobisphosphonates	136-156	farnesyl diphosphate synthase	Homo sapiens	0-29
21151198-1	2012	Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates.	aminobisphosphonates	136-156	farnesyl diphosphate synthase	Homo sapiens	31-35
21151198-8	2012	These results suggest that common polymorphisms of the FDPS gene influence the response to aminobisphosphonates.	aminobisphosphonates	91-111	farnesyl diphosphate synthase	Homo sapiens	55-59
22013129-2	2011	Aminobisphosphonates and alkylamines indirectly stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5"-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.	aminobisphosphonates	0-20	farnesyl diphosphate synthase	Homo sapiens	124-128
21069948-13	2010	gammadelta TCR, NKG2D and perforin-granzyme pathway are involved in the lysis of MCF-7 breast tumor cells treated with aminobisphosphonates by Vgamma9Vdelta2 T cells.	aminobisphosphonates	119-139	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	11-14
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	aminobisphosphonates	8-28	farnesyl diphosphate synthase	Homo sapiens	74-105
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	aminobisphosphonates	8-28	farnesyl diphosphate synthase	Homo sapiens	107-111
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	aminobisphosphonates	291-311	farnesyl diphosphate synthase	Homo sapiens	74-105
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	aminobisphosphonates	291-311	farnesyl diphosphate synthase	Homo sapiens	107-111
21647691-2	2011	Previous work has shown that aminobisphosphonates, including zoledronic acid (ZA), are capable of activating human Vgamma9 Vdelta2 T cells in vitro, and these cells can be further expanded with IL-2.	aminobisphosphonates	29-49	interleukin 2	Homo sapiens	194-198
21047568-1	2011	The acute-phase response (APR) to aminobisphosphonates is triggered by activation of gammadelta T cells, resulting in pro-inflammatory cytokine release.	aminobisphosphonates	34-54	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	26-29
21282739-1	2011	BACKGROUND/AIM: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate compounds, in particular geranylgeranyl-pyrophosphate (GGPP), which is associated with the consequent augmented IL-1beta release in monocytes.	aminobisphosphonates	157-177	interleukin 1 beta	Mus musculus	324-332
21069948-13	2010	gammadelta TCR, NKG2D and perforin-granzyme pathway are involved in the lysis of MCF-7 breast tumor cells treated with aminobisphosphonates by Vgamma9Vdelta2 T cells.	aminobisphosphonates	119-139	killer cell lectin like receptor K1	Homo sapiens	16-21
20554708-1	2010	CONTEXT: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied.	aminobisphosphonates	21-41	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	79-82
20304105-1	2010	The inhibition of mevalonate pathway through genetic defects (mevalonate kinase deficiency, MKD) or pharmacologic drugs (aminobisphosphonates) causes a shortage of intermediate compounds and, in particular, of geranylgeranyl-pyrophosphate (GGPP) associated to the activation of caspase-1 and IL-1beta release.	aminobisphosphonates	121-141	caspase 1	Homo sapiens	278-287
20304105-1	2010	The inhibition of mevalonate pathway through genetic defects (mevalonate kinase deficiency, MKD) or pharmacologic drugs (aminobisphosphonates) causes a shortage of intermediate compounds and, in particular, of geranylgeranyl-pyrophosphate (GGPP) associated to the activation of caspase-1 and IL-1beta release.	aminobisphosphonates	121-141	interleukin 1 beta	Homo sapiens	292-300
15244502-9	2004	However, a peculiar aspect concerning the action of non-aminobisphosphonates seems to be an anti-inflammatory activity caused by the inhibition of the release of inflammatory mediators from activated macrophages, such as interleukin (IL)-6, tumor necrosis factor-alpha and IL-1.	aminobisphosphonates	56-76	interleukin 1 alpha	Homo sapiens	273-277
19015945-6	2009	Using Face-1/Zmpste24-deficient mice as model, we found that a combination of statins and aminobisphosphonates inhibits both types of modifications of prelamin A and progerin, improves the ageing-like symptoms of these mice and extends substantially their longevity, opening a new therapeutic possibility for human progeroid syndromes associated with nuclear-envelope defects.	aminobisphosphonates	90-110	zinc metallopeptidase, STE24	Mus musculus	6-12
19015945-6	2009	Using Face-1/Zmpste24-deficient mice as model, we found that a combination of statins and aminobisphosphonates inhibits both types of modifications of prelamin A and progerin, improves the ageing-like symptoms of these mice and extends substantially their longevity, opening a new therapeutic possibility for human progeroid syndromes associated with nuclear-envelope defects.	aminobisphosphonates	90-110	zinc metallopeptidase, STE24	Mus musculus	13-21
16755241-6	2006	The mechanism of action is thought to be that aminobisphosphonates transiently stimulate the production of proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha.	aminobisphosphonates	46-66	interleukin 1 alpha	Homo sapiens	141-154
16755241-6	2006	The mechanism of action is thought to be that aminobisphosphonates transiently stimulate the production of proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha.	aminobisphosphonates	46-66	interleukin 6	Homo sapiens	156-169
16755241-6	2006	The mechanism of action is thought to be that aminobisphosphonates transiently stimulate the production of proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha.	aminobisphosphonates	46-66	tumor necrosis factor	Homo sapiens	175-202
16831298-2	2006	All tested aminobisphosphonates induce an IL-2-dependent activation and expansion of Vgamma9Vdelta2 T lymphocytes in primary PBMC cultures of healthy donors.	aminobisphosphonates	11-31	interleukin 2	Homo sapiens	42-46
16831298-4	2006	Accordingly, Vgamma9Vdelta2 T lymphocytes cultured with aminobisphosphonates and IL-2 showed a major content of IFN-gamma and acquired the ability to kill tumor target cells.	aminobisphosphonates	56-76	interferon gamma	Homo sapiens	112-121